Reinmann Aline, Bodmer Alexandre, Koessler Thibaud, Gligorov Joseph, Bruyneel Anne-Violette
Geneva School of Health Sciences, Physiotherapy Department, HES-SO University of Applied Sciences and Arts Western Switzerland, Rue des Caroubiers 25, Carouge, Geneva, CH-1227, Switzerland.
Sorbonne University, INSERM, Centre de Recherche Saint Antoine, CRSA, Paris, F-75012, France.
BMC Womens Health. 2025 May 30;25(1):269. doi: 10.1186/s12905-025-03790-4.
This study aimed to compare changes in postural control in different testing conditions involving sensory disturbances, quality of life and neurotoxicity concerns in women with cancer before and after chemotherapy with taxanes. The second aim was to compare postural control between chemotherapy-induced peripheral neuropathy (CIPN) severity subgroups.
The 33 participants with breast cancer (age 48.15 ± 9.88 years) were tested during the month preceding (baseline) and the month after the end of chemotherapy. Postural control was assessed on a force platform (100 Hz) in different conditions: eyes open/closed, rigid/foam surface, with/without tendon vibration, dual task, and limits of stability. CIPN severity and neurotoxicity concerns were also evaluated. Paired t-tests or Wilcoxon sign rank tests were used, and a Benjamini-Hochberg correction was applied.
After chemotherapy, greater postural adjustments were required to maintain balance in the reference condition (p ≤ 0.02), and in conditions with visual (p ≤ 0.02), foam (p ≤ 0.04), and dual task disturbances (p ≤ 0.01), but not in the vibration and limits of stability conditions. No difference was found between the CIPN subgroups. The neurotoxicity score worsened after chemotherapy (-8.61 ± 7.53, p ≤ 0.01).
Postural control was impaired after chemotherapy, particularly in conditions with visual disturbances and dual task. Anteroposterior center of pressure displacements with mediolateral ground reaction forces were particularly increased.
Systematic assessment of postural control with eyes closed in women with breast cancer would help to identify chemotherapy-induced postural control disorders and determine treatment needs.
Clinical Trial Registration number NCT04692168. Registration date: 28.12.2020.
本研究旨在比较紫杉烷类化疗前后癌症女性在涉及感觉障碍、生活质量和神经毒性问题的不同测试条件下姿势控制的变化。第二个目的是比较化疗引起的周围神经病变（CIPN）严重程度亚组之间的姿势控制。
33名乳腺癌患者（年龄48.15±9.88岁）在化疗前一个月（基线）和化疗结束后一个月接受测试。在不同条件下，使用测力平台（100Hz）评估姿势控制：睁眼/闭眼、硬表面/泡沫表面、有/无肌腱振动、双重任务以及稳定性极限。还评估了CIPN严重程度和神经毒性问题。使用配对t检验或Wilcoxon符号秩检验，并应用Benjamini-Hochberg校正。
化疗后，在参考条件下（p≤0.02）以及视觉干扰（p≤0.02）、泡沫干扰（p≤0.04）和双重任务干扰条件下（p≤0.01），需要更大的姿势调整来维持平衡，但在振动和稳定性极限条件下没有差异。CIPN亚组之间未发现差异。化疗后神经毒性评分恶化（-8.61±7.53，p≤0.01）。
化疗后姿势控制受损，尤其是在视觉干扰和双重任务条件下。前后压力中心位移与内外侧地面反作用力尤其增加。
对乳腺癌女性进行闭眼姿势控制的系统评估将有助于识别化疗引起的姿势控制障碍并确定治疗需求。
临床试验注册号NCT04692168。注册日期：2020年12月28日。
